Why the study?
Does troglitazone therapy prevent lipoapoptosis and loss of cardiac function in obese Zucker Diabetic Fatty rats?
Population
Obese Zucker Diabetic Fatty rats
Comparison
Troglitazone therapy vs Controls
Design
Preclinical
Authors
Loading...
Troglitazone prevents lipoapoptosis and cardiac dysfunction in obese rat model; hypothesis-generating for human diabetic cardiomyopathy.
Does troglitazone therapy prevent lipoapoptosis and loss of cardiac function in obese Zucker Diabetic Fatty rats?
In a rat model of obesity, cardiac dysfunction is driven by lipoapoptosis and can be prevented by lipid-lowering therapy with troglitazone.
Zhou et al. (2000) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: